Skip to main content
Dejan Juric, MD, Oncology, Boston, MA

Dejan Juric MD

Breast Cancer, Clinical Pharmacology


Director, Termeer Center for Targeted Therapies, Massachusetts General Hospital

Join to View Full Profile
  • 55 Fruit StBoston, MA 02114

  • Phone+1 617-726-6500

  • Fax+1 617-724-1079

Dr. Juric is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer Institute
    Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2009 - 2012
  • Mass General Brigham/Massachusetts General Hospital
    Mass General Brigham/Massachusetts General HospitalResidency, Internal Medicine, 2007 - 2009
  • University of Zagreb Faculty of Medicine
    University of Zagreb Faculty of MedicineClass of 2001

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 2011 - 2025
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • Alpelisib (ALP) with fulvestrant (FUL) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-)... 
    2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

  • Well-Designed Phase Ia and Ib Trials Point the Way to New Treatment Options
    Well-Designed Phase Ia and Ib Trials Point the Way to New Treatment OptionsMarch 5th, 2025
  • Evaluating Inavolisib vs Alpelisib plus Fulvestrant for Hormone Receptor-Positive, HER2-Negative, PIK3CA-Mutated Advanced Breast Cancer
    Evaluating Inavolisib vs Alpelisib plus Fulvestrant for Hormone Receptor-Positive, HER2-Negative, PIK3CA-Mutated Advanced Breast CancerSeptember 24th, 2024
  • Remembering José
    Remembering JoséMarch 30th, 2021
  • Join now to see all

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: